The drug failed to hit its Phase III targets.
Phase-IIIb study results indicate Lyxumia—which is approved abroad but not in the US—was "non-inferior" in terms of controlling blood sugar levels regardless of whether the shot was given before breakfast or later.
The commericalization/development deal covers up to six anti-cancer assets, and gives OncoMed a 50/50 US partnership over the experimental monoclonal antibody demcizumab.
The drugmaker revealed the data a year after stopping a Phase III trial.
The company is rolling out two new clinical trials, and Phase I data suggests an antidote could be on its way.
Early clinical trial results indicate 81% of advanced melanoma patients survived for one year.
New software is helping drugmakers troubleshoot clinical trials before recruitment.
The drugmaker says it will not pursue regulatory review of its Phase III JAK2 inhibitor fedratinib.
The EMA is wading through thousands of comments and may push back its clinical trial transparency initiative.
The company announced the layoffs Friday.
Data released at the Boston meeting of the American Association for the Study of Liver Diseases hints at an upcoming Gilead-Merck brawl.
Researchers think a two-hormone approach could help control diabetes and obesity.
A roundup of news related to hepatitis C.
Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.
The midnight shutdown put 800,000 government employees on leave, including those at the FDA, NIH and CDC.
The scandal over Diovan draws regulatory attention.
Phase III ramucirumab hit gastric cancer goals, but failed among breast cancer patients.
Sanofi has to provide more Aubagio data to the UK's NICE; healthcare reform's sixes and sevens; NIH puts money toward Alzheimer's research
Researches say cognitive enhancers, a group which includes drugs like Aricept and Exelon, fail to slow decline in patients with Alzheimer's over the long term.
Sanofi pulls GLP-1 diabetes med from FDA review; Gilead files oncology drug; BI/Lilly reveals results of head-to-head trial of its SGLT2 inhibitor vs. Januvia; BI campaign animates heartburn market; Girl Scouts take on mental health
Gilead in an other sofosbuvir IP fight; study says patients not sticking with Amgen's Brilinta; AstraZeneca and Cytokinetics drug fails to hit Phase II target; Otsuka gets a CRL
Researchers say a two-year study shows the DPP-IV drug is not linked to a higher cardiovascular risk.
Squeezed in the wet AMD space, Roche could get some eye-care breathing room if it can snag first-to-market status in the dry AMD category. Early results bode well.
Two of the most difficult-to-treat hepatitis C patient groups saw high cure rates in an NIH-led study, results released Tuesday show.
Takeda moves an Alzheimer's treatment to Phase III; Sangamo acquires Ceregene; Catalyst gets breakthrough designation for auto-immune disorder drug; study says seniors likely to opt out of health insurance
Phase II studies found recreational abusers were not significantly bothered by the mechanism meant to make a "deterrent" version unpleasant to snort.
Amgen's newest oncology asset could reach great heights, if the firm can capitalize on its existing commercial and R&D capabilities.
Allergan asks FDA to reconsider Restatis generics requirements, Incyte's Jakafi could be pancreatic cancer nemesis, Medtronic says its strategy is at the heart of where healthcare is going and Aetna's app alliance makes health local and personal.
The data suggest Boehringer's hep. C combo could find a treatment niche.
Phase III data for MannKind's Afrezza is positive, but past experience shows inhaled insulin may not be an immediate win.